Home

David P Schenkein

CIK 1578200 · Chief Executive Officer · last filed 2026-06-08

David P Schenkein is a Chief Executive Officer who has filed 130 SEC Form 4 insider transactions across 6 companies since 2013. The most recent filing, for PRME, was dated Jun 8, 2026. Across all open-market trades the lifetime net is −$70.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $14.9M across reported positions. 12 SEC filings were submitted jointly with bluebird bio, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$14.93M

Companies

6

Total Filings

130

Lifetime Open-Market Net

-$70.44M

Filer Profile

Reported Address
C/O BLUEBIRD BIO, INC.
840 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
Related Filers
bluebird bio, Inc. — 12 joint filings, latest 2020-06-22
REGENERON PHARMACEUTICALS, INC. — 5 joint filings, latest 2026-01-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PRME Director — $3.13 — $0 5 2026-06-08
DNLI Director 52,897 $21.09 $1.12M -$7.84M 17 2026-06-05
REGN Director 603 $781.49 $471.2K $0 4 2026-01-06
AGIO Director 397,014 $33.60 $13.34M -$62.02M 86 2024-06-24
bluebird bio, Inc. (BLUE) Delisted Director 342 $4.97 $1.7K -$577.8K 10 2020-06-22
Foundation Medicine, Inc. (FMI) Delisted Director 28,580 — — $0 5 2016-06-20

Recent Filings

130 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-08 PRME Grant (A) — $0 EDGAR
2026-06-05 DNLI Grant (A) +6,408 $0 EDGAR
2026-01-06 REGN Grant (A) +155 $0 EDGAR
2025-08-05 PRME Mixed — $0 EDGAR
2025-06-05 DNLI Grant (A) +6,037 $0 EDGAR
2025-06-05 PRME Grant (A) — $0 EDGAR
2025-01-06 REGN Grant (A) +166 $0 EDGAR
2024-11-13 DNLI Mixed −12,276 -$1.08M EDGAR
2024-11-12 DNLI Notice (144) −59,441 -$1.86M EDGAR
2024-06-24 AGIO Grant (A) — $0 EDGAR
Showing 1–10 of 130
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.